Phase III, Randomized, Observer Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Repeated Exposure to Either the Same or Alternate Type of Vaccine, Adjuvanted or Non-adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV or QIV), Administered to Subjects Previously Vaccinated in Trial V118_05 (NCT01964989)
Phase of Trial: Phase III
Latest Information Update: 23 Oct 2017
At a glance
- Drugs Influenza A H1N1 H3N2 influenza B Yamagata Victoria vaccine-Novartis (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Pharmacodynamics; Registrational
- Sponsors Novartis Vaccines; Seqirus
- 04 Jul 2017 Status changed from active, no longer recruiting to completed.
- 02 Sep 2016 Planned End Date changed from 1 Jul 2017 to 1 May 2017.
- 02 Sep 2016 Planned primary completion date changed from 1 Jul 2017 to 1 Oct 2016.